Bal Pharma Limited

What Bal Pharma Limited does

Bal Pharma Limited is an Indian pharmaceutical company founded in 1992 and headquartered in Bangalore, listed on the Bombay Stock Exchange (524824). The company operates across three core product lines: Active Pharmaceutical Ingredients (APIs), Finished Formulations (FDF), and Ayurvedic/herbal products under the Bal Vedics brand. Its API business, launched in 1996, produces niche molecules with vertical integration from intermediates to finished APIs, supported by R&D for patent non-infringing processes and Drug Master File (DMF) documentation. Finished formulations span tablets, capsules, syrups, suspensions, IV infusions, ophthalmic preparations, creams, and ointments across 200+ formulations in 20 therapeutic segments.

The company operates six manufacturing facilities across India — Units 1 and 2 in Bangalore (finished dosage and API), Unit 3 in Pune (IV fluids and ophthalmic), Unit 4 in Rudrapur (tablets, capsules, creams/ointments), Unit 5 in Sangli (intermediates), and Unit 6 in Udaipur (APIs). Combined annual capacity exceeds 3.6 billion tablets, 500 million capsules, 240 tonnes of APIs, and 29 million vials/bottles of IV and liquid preparations. Manufacturing facilities are accredited to EUGMP, UKMHRA, WHO-TRS, USFDA, EDQM, TGA Australia, PMDA Japan, MOH Canada, KFDA Korea, COFEPRIS Mexico, and ANVISA Brazil standards.

Bal Pharma's business model combines domestic distribution through a 500+ field force with super stockists across India, plus direct international exports to more than 80 countries spanning regulated markets (Japan, Australia, Europe, Canada) and semi-regulated markets. The company sells through therapeutic divisions domestically (Vibrant for multi-specialty, Glyduz for diabetic care, Servetus for cardiac care, Bal Vedics for ayurvedic) and through direct sales teams for API and international tenders. Customer segments include government institutions (registered vendor for major Indian government bodies and hospitals), international generic formulators, and retail pharmacies via stockists. Revenue is generated primarily through product sales (APIs and formulations) with no disclosed subscription or licensing model. Recent corporate moves include the NCLT-approved merger of Golden Drugs Pvt Ltd (March 2025), a 1.5 MW captive solar power project, and an ESG partnership with rePurpose Global for plastic waste recovery.

Name

Bal Pharma Limited

Legal name

Bal Pharma Limited

Website

https://balpharma.com

Company type

Public

Founded year

1992

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Bal Pharma Limited is a Bangalore-based Indian pharmaceutical manufacturer (BSE: 524824) producing APIs, finished formulations, and Ayurvedic products across six manufacturing facilities, exporting to 80+ countries and selling domestically through a 500+ field force.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

akta.pro secondary industry

Cold, Flu, Cough & Allergy Remedies (Decongestants, Antihistamines, Cough Syrups, Lozenges) (CRADAMAD)

Keywords

• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Finished dosage formulations
• Ayurvedic medicines
• Generic pharmaceuticals

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

1. Active Pharmaceutical Ingredients (API): Manufacturing and export of niche molecule APIs. APIs exported to Europe, Far East, Latin America, Africa, Middle East and other World markets. Vertical integration benefits from intermediate manufacturing to finished APIs.
2. Finished Formulations (FDF): Finished dosage forms including tablets, capsules, syrups, suspensions, IV infusions, ophthalmic, creams and ointments exported to semi-regulated and non-regulated markets, now foraying into regulated markets.
3. Domestic Formulation Sales: Prescription drugs, branded formulations, generics, OTC products, and intravenous infusions sold domestically through field force and distribution network.
4. Ayurvedic/Herbal Products: Natural Ayurvedic formulations integrating traditional Indian wisdom with scientific manufacturing, including 16-17 natural medicines.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels4 records

Core offering

Bal Pharma Limited manufactures and sells pharmaceutical products including active pharmaceutical ingredients (APIs) and finished formulations such as tablets, capsules, syrups, IV infusions, ophthalmic preparations, creams, and ointments. The company also produces Ayurvedic medicines and operates across institutional, domestic, and export markets, supplying pharmaceutical products to over 80 countries.

Product overview

Bal Pharma Limited is a pharmaceutical company operating as a single unified manufacturer with three core product lines: Active Pharmaceutical Ingredients (APIs), Finished Formulations, and Ayurvedic/Herbal products (Bal Vedics). The company manufactures pharmaceutical products across six facilities in India and exports to more than 80 countries. APIs and Finished Formulations are produced at world-class manufacturing facilities, with APIs exported to regulated markets (Europe, Japan, Australia) and finished formulations exported to semi-regulated and non-regulated markets while foraying into regulated markets. The company also operates domestic marketing divisions including Vibrant (multi-specialty), Glyduz (diabetic care), Servetus (cardiac care), and Bal Vedics (ayurvedic). The portfolio includes more than 200 formulations covering 20 therapeutic segments and 16-17 ayurvedic products.

Differentiator

Problem solved

Functional benefit

Brands

• Bal Vedics: Ayurvedic division launched in 2003, integrating modern medicine with Ayurvedic/herbal preparations for various therapeutic areas including prostate enlargement, renal calculi, male infertility, and women's health.
• Vibrant
• Glyduz
• Servetus
• Bal Vedics

Products and services

• Active Pharmaceutical Ingredients (APIs)

Quantifiable outcome

• USD 30 Million revenue company with 32+ years of experience
• +2 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• rePurpose GlobalcoreStrategic or Co-development PartnerBal Pharma Limited partnered with rePurpose Global to recover 60,000 kg of plastic waste in India as part of its ESG commitment. This initiative supports responsible waste management and contributes to a circular economy, equivalent to roughly 4.12 crore Paracetamol blister strips.
• Adarsh VidyasanghminorOthersBal Pharma supports education in the local community by providing scholarships to economically disadvantaged students studying at the Adarsh Group of Institutions, in association with Adarsh Vidyasangh.
• Rotary Bangalore BrigadesminorOthersBal Pharma, in association with Rotary Bangalore Brigades, donated essential medical equipment to primary healthcare centers, supporting improved access to basic healthcare services for local communities.
• Jain Mission Trust, ChikkaballapurminorOthersBal Pharma supported one month of free dialysis treatment for patients with kidney malfunction in association with Jain Mission Trust, Chikkaballapur. This initiative aimed to improve access to essential, life-sustaining healthcare for patients in need.
• LifeZen Healthcare Pvt LtdcoreStrategic or Co-development PartnerLifeZen is a subsidiary of Bal Pharma Limited, operating as a healthcare venture focused on wellness and pharmaceutical products.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• Cipla Limited: Major Indian pharmaceutical incumbent with global API and formulation operations across respiratory, cardiac, anti-diabetic and other therapeutic areas where Bal Pharma also competes via its Vibrant, Glyduz and Servetus divisions.
• Aurobindo Pharma Limited: Large Indian pharma with vertically integrated API and generic formulation operations across multiple dosage forms and over 150 countries, sitting in the same value chain but at materially greater scale.
• Ajanta Pharma Limited: Indian branded and generic formulations exporter with manufacturing across multiple therapeutic segments, comparable in therapeutic coverage but larger and more brand-driven than Bal Pharma.
• Sun Pharmaceutical Industries Limited: Largest Indian pharma player with extensive API and specialty generics footprint worldwide; provides a benchmark incumbent competitor across therapeutic areas Bal Pharma serves.
• Jubilant Pharmova Limited: Indian pharma with API and dosage form manufacturing serving global markets; overlaps with Bal Pharma in API capabilities and export-oriented model but operates at significantly larger scale.

Direct peers

• Granules India Limited: Indian publicly listed manufacturer of APIs and finished dosages exporting to regulated and semi-regulated markets with comparable vertical integration, making it a near-direct comp on portfolio and geographic mix.
• Ipca Laboratories Limited: Indian pharma player with strong API manufacturing footprint and finished formulations exported to regulated and emerging markets; comparable API-to-formulation model and international approval profile.
• Unichem Laboratories Limited: Mid-sized Indian generic pharma with API and formulation manufacturing for domestic and international markets, broadly overlapping Bal Pharma's therapeutic breadth and export orientation.
• Strides Pharma Science Limited: Indian specialty generics manufacturer focused on regulated and emerging markets with API and formulation capabilities; closely mirrors Bal Pharma's regulated/semi-regulated export strategy.
• Alembic Pharmaceuticals Limited: Indian manufacturer of generic APIs and formulations with USFDA-inspected facilities, serving similar therapeutic segments and export markets as Bal Pharma.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance39 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries5 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bal Pharma Limited